Compare LKFN & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LKFN | PGEN |
|---|---|---|
| Founded | 1872 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2009 | 2013 |
| Metric | LKFN | PGEN |
|---|---|---|
| Price | $60.00 | $3.60 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $67.00 | $8.33 |
| AVG Volume (30 Days) | 159.5K | ★ 4.2M |
| Earning Date | 04-27-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.49% | N/A |
| EPS Growth | ★ 10.47 | N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | $985,000.00 | ★ $230,981,000.00 |
| Revenue This Year | $15.50 | $1,115.92 |
| Revenue Next Year | $5.51 | $81.04 |
| P/E Ratio | $57.01 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $54.36 | $1.38 |
| 52 Week High | $69.38 | $5.47 |
| Indicator | LKFN | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 53.19 | 36.15 |
| Support Level | $58.03 | $3.49 |
| Resistance Level | $60.94 | $3.64 |
| Average True Range (ATR) | 1.35 | 0.27 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 81.49 | 7.39 |
Lakeland Financial Corp is a bank holding company. It provides commercial, retail, wealth advisory, and investment management services. It offers a broad line of products and services throughout its Northern and Central Indiana markets. The company provides commercial and consumer banking services, as well as trust and wealth management, brokerage, and treasury management commercial services. It serves a wide variety of industries including, among others, commercial real estate, manufacturing, agriculture, construction, retail, wholesale, finance and insurance, accommodation and food services, and healthcare. The company's revenue is derived from the business of banking.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.